{"organizations": [], "uuid": "6922d7bf426bc5d5f6ededc33fa4829d95bf12eb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-accepts-remoxy-nda-for-reviews/brief-fda-accepts-remoxy-nda-for-reviewsets-pdufa-date-of-aug-7-2018-idUSASB0C8B5", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T15:21:00.000+02:00", "replies_count": 0, "uuid": "6922d7bf426bc5d5f6ededc33fa4829d95bf12eb"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-accepts-remoxy-nda-for-reviews/brief-fda-accepts-remoxy-nda-for-reviewsets-pdufa-date-of-aug-7-2018-idUSASB0C8B5", "ord_in_thread": 0, "title": "BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nda for review", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1, 2018 / 1:22 PM / in 10 minutes BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018 Reuters Staff March 1 (Reuters) - Pain Therapeutics Inc: * FDA ACCEPTS REMOXYÂ® NDA FOR REVIEW, SETS PDUFA DATE OF AUGUST 7, 2018 * U.S. FDA DETERMINED THAT A NDA FOR REMOXY ER IS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW * FDA HAS SET AN ACTION DATE OF AUGUST 7, 2018 UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA) * PAIN THERAPEUTICS -BELIEVES FDA WILL HOLD AN OPEN ADVISORY COMMITTEE MEETING TO DISCUSS REMOXY ER, ALTHOUGH A DATE HAS NOT YET BEEN DETERMINED. Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-01T15:21:00.000+02:00", "crawled": "2018-03-01T15:42:34.037+02:00", "highlightTitle": ""}